Tanzanian drug trade liberalization warning

27 May 2001

Drugs are a vital element in ensuring community health but, as a resultof trade liberalization, they are "being sold like sweets," according to the president of the Pharmaceutical Society of Tanzania, Romuald Mbwasi.

Dr Mbwasi said that medicines were most vulnerable to the liberalization policies, as anyone with sufficient money could start up a pharmacy. In many cases, pharmacies were being started up as "part two" drugstores, selling over-the-counter products only, "where basic knowledge about drugs is not an issue," he said.

Dr Mbwasi warned that the incorrect, improper use of drugs had long-term national implications, because it could not only cost the lives of future generations but also result in huge financial losses to the state. Consumers would build up resistance to simple drugs and then be forced to buy more expensive ones, he said.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight